Single Dose Escalation Study of GSK2838232 in Healthy Subjects
Status:
Completed
Trial end date:
2013-11-21
Target enrollment:
Participant gender:
Summary
GSK2838232 is a novel human immune virus (HIV) maturation inhibitor being developed for the
treatment of chronic HIV infection. This study is the first administration of GSK2838232 in
humans to establish the initial safety, tolerability, and pharmacokinetic profile following
single doses of GSK2838232 and to evaluate the effect of food and ritonavir (RTV) on
GSK2838232 in healthy subjects. There will be 2 cohorts in this study. In Cohort 1,
approximately 8 healthy subjects will be enrolled (6 active and 2 placebo) at each dose
visit. There will be four dosing sessions for each subject with subjects randomized to
receive placebo in a random sequence. In Cohort 2, approximately 8 healthy subjects will be
enrolled (6 active doses and 2 placebo doses at each dose visit). Cohort 2 will have four
dosing sessions for each subject with subjects randomized to receive placebo in a random
sequence.